Holen Sie sich die Stockscreener-App
163.36
9.06%
13.57
Handel nachbörslich:
163.36
Schlusskurs vom Vortag:
$149.79
Offen:
$157.42
24-Stunden-Volumen:
1.88M
Relative Volume:
1.68
Marktkapitalisierung:
$8.02B
Einnahmen:
$4.06B
Nettoeinkommen (Verlust:
$413.08M
KGV:
20.39
EPS:
8.01
Netto-Cashflow:
$560.48M
1W Leistung:
+5.79%
1M Leistung:
+10.79%
6M Leistung:
-2.89%
1J Leistung:
-28.23%
1-Tages-Spanne:
$155.48
$167.83
1-Wochen-Bereich:
$146.26
$167.83
52-Wochen-Spanne:
$91.86
$254.15
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Vergleichen Sie CRL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
163.36 | 7.58B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
427.62 | 157.79B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.91 | 138.02B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
532.00 | 42.36B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
116.19 | 32.08B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
187.38 | 27.28B | 15.50B | 1.33B | 2.16B | 7.34 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
What analysts say about Charles River Laboratories International Inc. stockOutstanding capital returns - jammulinksnews.com
What drives Charles River Laboratories International Inc. stock priceMarket-crushing stock picks - Autocar Professional
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Labs Stock Rises on Plasmid DNA Deal with Ellys TeamNews and Statistics - IndexBox
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Why Are Charles River Laboratories (CRL) Shares Soaring Today - Yahoo Finance
Is Charles River Laboratories International Inc. a good long term investmentRapid-fire capital growth - jammulinksnews.com
Gene Therapy Breakthrough: Charles River Helps Develop First Treatment for Ultra-Rare Disease in Just 13 Months - Stock Titan
Here's What to Expect From Charles River Laboratories' Next Earnings Report - MSN
Charles River Laboratories International Inc. Stock Analysis and ForecastHigh-velocity capital appreciation - jammulinksnews.com
How Charles River Laboratories International Inc. stock reacts to Fed policy changesReal Chart Play - beatles.ru
Is it Prudent to Retain Charles River Stock in Your Portfolio Now? - MSN
Agree To Purchase Charles River Laboratories International At $150, Earn 21.4% Annualized Using Options - Nasdaq
Pharma Contract Research Organization (CRO) Services Market to Cross USD 36.66 Billion in 2025, Expanding at a CAGR of 10.04% - GlobeNewswire Inc.
Here's What To Expect From Charles River Laboratories' Next Earnings Report - Barchart.com
Is Charles River Laboratories International (NYSE:CRL) Using Too Much Debt? - simplywall.st
Why Charles River Laboratories International Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - beatles.ru
CFRA downgrades Charles River Labs (CRL) to a Hold - The Globe and Mail
Gordon Reid discusses Charles River Laboratories Intl. Inc - BNN Bloomberg
Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call - BioSpace
Charles River Laboratories International (CRL) is Expected to Gain as Industry Growth Resumes - Insider Monkey
U.S. Physical Therapy, Evolent Health, Charles River Laboratories, Moderna, and Intuitive Surgical Shares Are Falling, What You Need To Know - FinancialContent
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Charles River Labs (CRL) - The Globe and Mail
Evercore ISI Adjusts PT on Charles River Laboratories International to $180 From $170 - MarketScreener
This Microsoft Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Charles River Labs stock rating upgraded by Citi on DSA growth prospects - Investing.com Canada
Cathie Wood Agrees Circle IPO Is 'Crypto's ChatGPT Moment' — Warns Institutions That Ignoring The AI-Crypto Combo 'Just Isn't An Option'Charles River (NYSE:CRL) - Benzinga
Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
5 Revealing Analyst Questions From Charles River Laboratories’s Q1 Earnings Call - Yahoo Finance
Is Charles River Laboratories Stock Underperforming the S&P 500? - MSN
Charles River Laboratories: FDA Regulation And High Debt Are Signs Of Headwinds - Seeking Alpha
Charles River Laboratories: Riding the AI Drug Discovery Wave Amid Regulatory Crosscurrents - AInvest
Shareholders in Charles River Laboratories International (NYSE:CRL) are in the red if they invested three years ago - simplywall.st
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment | CRL Stock News - GuruFocus
Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment - Business Wire
Do Wall Street Analysts Like Charles River Laboratories Stock? - MSN
Global Viral Inactivation Market | Solvent Detergent & - openPR.com
Charles River falls after projecting 2025 revenue drop - MSN
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.06%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):